Mobocertinib

Mobocertinib (TAK788) is a small molecule tyrosine kinase inhibitor, from Takeda that is currently under development for the treatment of non-small cell lung cancer. Its molecular target is EGFR bearing mutations in the exon 20 region.
EGFR exon 20 insertions are a rare subset of all EGFR mutation types observed in non-small cell lung cancer. EGFR inhibitors used currently for the treatment of NSCLC are only active against EGFR L858R point mutations and exon 19 deletions, and have minimal clinical activity against exon 20 insertions.